A Blinded Randomized Trial Comparing Standard Activated Clotting Time Heparin Management to High Target Active Clotting Time and Individualized Hepcon HMS Heparin Management in Cardiopulmonary Bypass Cardiac Surgical Patients.

ABSTRACT:

Purpose

High-dose heparin has been suggested to reduce consumption coagulopathy.

Materials and methods

In a randomized, blinded, prospective trial of patients undergoing elective, complex cardiac surgery with cardiopulmonary bypass, patients were randomized to one of three groups: 1) high-dose heparin (HH) receiving an initial heparin dose of 450 u/kg, 2) heparin concentration monitoring (HC) with Hepcon Hemostasis Management System (HMS; Medtronic, Minneapolis, MN, USA) monitoring, or 3) a control group (C) receiving a standard heparin dose of 300 u/kg. Primary outcome measures were blood loss and transfusion requirements.

Results

There were 269 patients block randomized based on primary versus redo sternotomy to one of the three groups from August 2001 to August 200

SUBMITTER: Nuttall GA 

PROVIDER: S-EPMC9209891 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature